Welcome to our dedicated page for Io Biotech news (Ticker: IOBT), a resource for investors and traders seeking the latest updates and insights on Io Biotech stock.
IO Biotech, Inc. (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. This news page aggregates company announcements, clinical updates, financial disclosures, and regulatory communications related to IO Biotech and its lead investigational cancer vaccine candidate, Cylembio® (IO102-IO103).
Readers can find coverage of clinical trial milestones, including data from the pivotal Phase 3 IOB-013/KN-D18 trial of Cylembio plus KEYTRUDA® (pembrolizumab) in advanced melanoma and Phase 2 basket trials in non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), and other solid tumors. News items also highlight long-term outcomes from earlier-phase studies, such as the MM1636 Phase 1/2 trial, and pre-clinical data for additional T-win platform candidates IO112 and IO170.
Investors and followers of IOBT can review regulatory and corporate updates, including the company’s reports on FDA interactions regarding Cylembio, workforce restructuring plans, and participation in major medical and investor conferences. Financial press releases provide quarterly results, operating expense trends, cash position commentary, and details on financing arrangements such as the European Investment Bank term loan facility and associated warrants.
This page is useful for tracking how IO Biotech communicates progress on its immune-modulatory cancer vaccine programs, interprets key efficacy and safety results, and describes its ongoing engagement with regulators and collaborators. For those monitoring IOBT stock or the broader immuno-oncology field, the news feed offers a centralized view of the company’s scientific presentations, trial readouts, and strategic business developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IO Biotech announced significant progress in its clinical trials and financial results for 2022. The company expects to enroll 75% of patients in its Phase 3 trial (IOB-013/KN-D18) for advanced melanoma by mid-2023, with full enrollment anticipated by year-end. An interim analysis could lead to a Biologics License Application for accelerated approval in the US. The Phase 2 basket study (IOB-022/KN-D38) continues to recruit patients, with data expected soon. Financially, IO Biotech reported a net loss of $71.5 million for 2022 and ended the year with $142.6 million in cash, expected to last through Q3 2024.
IO Biotech (Nasdaq: IOBT) announced its participation in two investor conferences scheduled for March 2023. President and CEO, Mai-Britt Zocca, will join the Novel IO Panel at the Cowen 43rd Annual Health Care Conference from March 6-8 in Boston, and will also present at the Oppenheimer 33rd Annual Healthcare Conference virtually from March 13-15. During both events, Dr. Zocca and CFO Amy Sullivan will be available for one-on-one meetings with investors. The company is focused on developing immune-modulating cancer therapies with its T-win® vaccine platform, targeting IDO and PD-L1 with its leading candidate, IO102-IO103.
IO Biotech has appointed Devin Smith as its first General Counsel and Chief Compliance Officer, bringing over 25 years of legal experience in the life sciences sector. Smith's role will involve overseeing legal activities and corporate governance, contributing to the company’s growth and pipeline advancements.
Smith previously held senior legal positions at Yumanity Therapeutics and Minerva Neurosciences, where he played key roles in significant transactions, including a $155 million deal. His expertise is expected to enhance IO Biotech’s operations as it develops immune-modulating cancer vaccines, including the IO102-IO103 candidate.
IO Biotech (Nasdaq: IOBT) reported a positive update on its clinical trials for IO102-IO103. An independent monitoring committee recommended that the Phase 3 trial in advanced melanoma continue without modifications, with over 80 sites enrolled globally. Encouraging preliminary data from a Phase 2 trial showed a partial response in 4 out of 9 lung cancer patients. The company is also set to support a study with Johns Hopkins University for head and neck cancer, expected to start in H1 2023. IO Biotech ended 2022 with approximately $142.7 million in cash, sufficient to support operations into mid-2024.
IO Biotech presented preclinical data for two new pipeline candidates targeting the immunosuppressive effects of Arginase-1 (ARG1) and Transforming Growth Factor Beta 1 (TGFβ1) during the SITC 37th Annual Meeting on November 10-11, 2022. CEO Mai-Britt Zocca highlighted promising results from the Phase 1/2 study of their lead asset, IO102-103, confirming efficacy in treating metastatic melanoma. The company plans to file Investigational New Drug applications for the new candidates in 2023, indicating ongoing progress in their clinical studies.